Danaher continues to actively monitor the COVID-19 pandemic and has taken and intends to continue taking steps to identify and mitigate the adverse impacts on, and risks to, its employees, customers, business partners, manufacturing capabilities and capacity, and supply and distribution channels; its businesses have activated their business continuity plans in response to the pandemic, including taking steps to help keep the workforce healthy and safe, and are assessing and updating those plans on an ongoing basis; as a result of COVID-19 the company has modified business practices—ranging from employee travel and work locations to cancellation of physical meetings, events and conferences—and developed return-to-work protocols designed to help ensure the health and safety of employees, customers and business partners as conditions permit; the company is working with suppliers to understand existing and potential future negative impacts to its supply chain and to take actions to mitigate such impacts, and to date has not experienced significant supply chain disruptions; the company’s geographic and industry diversity, as well as the range of its products, software and services, help limit the impact of any one industry or economy on its consolidated operating results; management’s discussion and analysis focuses on material events and uncertainties known to management that are reasonably likely to cause reported financial information not to be indicative of future results, and management assesses liquidity in terms of its ability to generate cash to fund operating, investing and financing activities; the company believes its operating cash flow and other sources of liquidity will be sufficient to allow it to continue investing in existing businesses, consummating strategic acquisitions and investments, paying interest and servicing debt, funding restructuring activities and managing its capital structure on both a short- and long-term basis; to address volatility in interest rates and foreign exchange rates, it employs a mixture of fixed-rate and variable-rate debt, utilizes commercial paper programs and committed credit facilities, and enters into cross-currency swap and other derivative contracts; the company is making significant investments, both organically and through acquisitions, to address rapid technological change in its served markets and to globalize its manufacturing, research and development and customer-facing resources in order to be responsive to customers worldwide and improve operational efficiency; the acquisition of Cytiva on March 31, 2020 has provided, and is expected to continue to provide, additional sales and earnings growth opportunities for the Life Sciences segment by expanding geographic and product line diversity—including complementary product and service offerings—reflecting the company’s ability to reconfigure resources and adapt to external disruptions; and the company has deployed its capabilities, expertise and scale to develop and make available rapid diagnostic tests for COVID-19 and to support firms developing and producing vaccines, exemplifying its capacity to transform in response to challenging conditions and emerge stronger.